Why switching from conventional models to Organs on Chips?
Whereas 2D culture models are able to provide large amounts of relatively inexpensive data, this type of model weakly represent the complex pathophysiology in patients. In addition, they often require computational modeling and systems biology approaches to predict in vivo drug responses.
Figure 1: Schematic representation of the components of a hypothetical integrated microphysiological system (MPS). From John P Wikswo, 2014, Experimental Biology and Medicine
The World Fastest
temperature controller for live cell imaging
The full content has moved to our new website. Get full access by following the link below.
https://innovation.cherrybiotech.com/organs-on-a-chip/organ-on-chips-and-drug-development
Discover the CherryTemp Heater Cooler
Ultra-fast shifts and temperature accuracy at the sample level
Bibliography/Sources
1) Aref AR, et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integr Biol (Camb). 2013; 5:381–389. [PubMed: 23172153]
2) Snouber LC, et al. Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol Sci. 2013; 132:8–20
3) Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip. 2013; 13:3599–3608.
4) LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol. 2012; 42:501–548.
5) Chao P, Maguire T, Novik E, Cheng K-C, Yarmush M. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol. 2009; 78:625–632.
6) Kim HJ, Huh D, Hamilton G, Ingber DE. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip. 2012; 12:2165–2174.
(7)Wang G, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nature Med. 2014; 20:616–623.
(8) Wang G, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nature Med. 2014; 20:616–623.
Pierre is incubated in our Entrepreneurship school. LEARN MORE.
